Literature DB >> 25755489

Current status of immunosuppression in liver transplantation.

Narendra S Choudhary1, Sanjiv Saigal1, Rajat Shukla2, Hardik Kotecha1, Neeraj Saraf1, Arvinder S Soin1.   

Abstract

With advancements in immunosuppressive strategies and availability of better immunosuppressive agents, survival rate following liver transplantation has improved significantly in the recent times. Besides improvements in surgical techniques, the most important factor that has contributed to this better outcome is the progress made in the field of immunosuppression. Over the last several years, the trend has changed to tailored immunosuppression with the aim of achieving optimal graft function while avoiding its undesirable side effects. Induction agents are no longer used routinely and the aim is to provide minimal immunosuppression in the maintenance phase. The present review discusses the various types of immunosuppressive agents, their mechanism of action, clinical utility, advantages and disadvantages, and their side effects in short and long-term. It also discusses about tailoring immunosuppression in presence of various situations such as renal dysfunction, metabolic syndrome, hepatitis C recurrence, cytomegalovirus infections and so on. The issue of chronic kidney disease and the available renal sparing immunosuppressive strategies has been particularly stressed upon. Finally, it discusses about the practical aspects of various immunosuppression regimens including drug monitoring.

Entities:  

Keywords:  ACR, acute cellular rejection; ATP, adenosine triphosphate; CKD, chronic kidney disease; CNI, Calcineurin inhibitor; FKBP12, FK506 binding protein; HCV, hepatitis C virus; HLA, human leukocyte antigen; IL-2, interleukin-2; MAP, mitogen activated protein; MPA, mycophenolic acid; MS, metabolic syndrome; NF-kB, nuclear factor kappa B; NFAT, nuclear factor of activated T cells; PTLD, post-transplant lymphoproliferative disease; immunosuppression; liver transplantation; mTORC1, mammalian target of rapamycin complex 1; metabolic syndrome

Year:  2013        PMID: 25755489      PMCID: PMC3940114          DOI: 10.1016/j.jceh.2013.04.005

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  88 in total

Review 1.  Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy.

Authors:  Anna L Taylor; Christopher J E Watson; J Andrew Bradley
Journal:  Crit Rev Oncol Hematol       Date:  2005-10       Impact factor: 6.312

Review 2.  Calcineurin inhibitor nephrotoxicity.

Authors:  Maarten Naesens; Dirk R J Kuypers; Minnie Sarwal
Journal:  Clin J Am Soc Nephrol       Date:  2009-02       Impact factor: 8.237

Review 3.  Next level of immunosuppression: drug/immune monitoring.

Authors:  Josh Levitsky
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

Review 4.  The immunoreactive patient: Rejection and autoimmune disease.

Authors:  John O'Grady
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

5.  Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.

Authors:  Carlo B Ramirez; Cataldo Doria; Fabrizio di Francesco; Maurizio Iaria; Yoogoo Kang; Ignazio R Marino
Journal:  J Surg Res       Date:  2007-02-08       Impact factor: 2.192

6.  A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT.

Authors:  L Fischer; J Klempnauer; S Beckebaum; H J Metselaar; P Neuhaus; P Schemmer; U Settmacher; N Heyne; P-A Clavien; F Muehlbacher; I Morard; H Wolters; W Vogel; T Becker; M Sterneck; F Lehner; C Klein; G Kazemier; A Pascher; J Schmidt; F Rauchfuss; A Schnitzbauer; S Nadalin; M Hack; S Ladenburger; H J Schlitt
Journal:  Am J Transplant       Date:  2012-04-11       Impact factor: 8.086

7.  Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment.

Authors:  Upton Allen; Caroline Alfieri; Jutta Preiksaitis; Atul Humar; Dorothy Moore; Bruce Tapiero; Raymond Tellier; Michael Green; Dele Davies; Diane Hébert; Sheila Weitzman; Martin Petric; Kevan Jacobson
Journal:  Can J Infect Dis       Date:  2002-03

8.  A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.

Authors:  Christopher J E Watson; Alexander E S Gimson; Graeme J Alexander; Michael E D Allison; Paul Gibbs; Jane C Smith; Christopher R Palmer; J Andrew Bradley
Journal:  Liver Transpl       Date:  2007-12       Impact factor: 5.799

9.  New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells.

Authors:  W Li; C S Kuhr; X X Zheng; K Carper; A W Thomson; J D Reyes; J D Perkins
Journal:  Am J Transplant       Date:  2008-06-12       Impact factor: 8.086

10.  Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.

Authors:  P De Simone; F Nevens; L De Carlis; H J Metselaar; S Beckebaum; F Saliba; S Jonas; D Sudan; J Fung; L Fischer; C Duvoux; K D Chavin; B Koneru; M A Huang; W C Chapman; D Foltys; S Witte; H Jiang; J M Hexham; G Junge
Journal:  Am J Transplant       Date:  2012-08-06       Impact factor: 8.086

View more
  10 in total

1.  Hepatobiliary quiz-7 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-09

2.  Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.

Authors:  Katalin Monostory; Katalin Tóth; Ádám Kiss; Edit Háfra; Nóra Csikány; József Paulik; Enikő Sárváry; László Kóbori
Journal:  Br J Clin Pharmacol       Date:  2015-10-26       Impact factor: 4.335

3.  Hepatobiliary quiz-8 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-12

Review 4.  Preventive Strategies for Nonalcoholic Fatty Liver Disease After Liver Transplantation.

Authors:  Narendra S Choudhary; Sanjiv Saigal
Journal:  J Clin Exp Hepatol       Date:  2019-05-30

Review 5.  Acute and Chronic Rejection After Liver Transplantation: What A Clinician Needs to Know.

Authors:  Narendra S Choudhary; Sanjiv Saigal; Rinkesh K Bansal; Neeraj Saraf; Dheeraj Gautam; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2017-11-07

6.  A Case of Sirolimus-Induced Interstitial Lung Disease After Liver Transplantation.

Authors:  Narendra S Choudhary; Sanjiv Saigal; Amey Sonavane; Ashish K Prakash; Arvind Pandey; Neeraj Saraf; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2018-10-05

7.  Nonalcoholic Fatty Liver Disease in Living Donor Liver Transplant Recipients: A Histology-Based Study.

Authors:  Narendra S Choudhary; Neeraj Saraf; Swapnil Dhampalwar; Saurabh Mishra; Dheeraj Gautam; Lipika Lipi; Amit Rastogi; Prashant Bhangui; Rohan J Chaudhary; Ankur Gupta; Kamal Yadav; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2022-05-05

Review 8.  Long-term Management of the Adult Liver Transplantation Recipients.

Authors:  Narendra S Choudhary; Neeraj Saraf; Sanjiv Saigal; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2020-07-02

9.  Individualized Immunosuppressive Protocol of Liver Transplant Recipient Should be Made Based on Splenic Function Status.

Authors:  Ji-Yong Song; Guo-Sheng Du; Li Xiao; Wen Chen; Long-Long Suo; Yu Gao; Li-Kui Feng; Bing-Yi Shi
Journal:  Chin Med J (Engl)       Date:  2016-06-05       Impact factor: 2.628

10.  An Assessment of Publication Status of Pediatric Liver Transplantation Studies.

Authors:  Thomas Breil; Daniel Wenning; Ulrike Teufel; Georg F Hoffmann; Markus Ries
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.